[{"id":"6aff2aba-35a1-4846-94a9-768893c1feac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05234606","created_at":"2022-02-10T13:52:58.124Z","updated_at":"2024-07-02T16:36:12.983Z","phase":"Phase 1/2","brief_title":"A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors","source_id_and_acronym":"NCT05234606","lead_sponsor":"Silverback Therapeutics","biomarkers":" HER-2 • NECTIN4","pipe":" | ","alterations":" HER-2 negative • NECTIN4 expression","tags":["HER-2 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SBT6290"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/31/2022","primary_completion_date":" 03/31/2022","study_txt":" Completion: 03/31/2022","study_completion_date":" 03/31/2022","last_update_posted":"2022-04-12"}]